Although COVID-19 has claimed the headlines the past two years, bacterial infections represent an urgent and ever growing threat to human health worldwide. Over the past decades, pan-resistant strains of major bacterial pathogens have emerged rendering clinically available antibiotics ineffective. As a result, many achievements of modern medicine are now at risk. New ways to identify clinically effective antimicrobials are urgently needed to counter this threat.
However, the current antimicrobial development pipeline is insufficient because of high attrition rates and limited coverage of multi-drug resistant Gram-negative bacteria.
This conference aligns with the scope of the National Center of Competence in Research “AntiResist” which aims at revitalizing antibiotic discovery by bringing a patient-centered paradigm shift. Such a shift requires a multidisciplinary approach starting at the bedside. This EMBO workshop bids to review the current knowledge on bacterial physiology in patients; outline the development of relevant in vitro models to study the underlying molecular mechanisms and provide an overview of novel intervention strategies.
Bringing together the world’s foremost scientists in the field of antimicrobial research will help close the gap between the bedside and the bench and will enable to accelerate the clinical development of new antimicrobial therapies to win the race against superbugs.